Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| IDEAYA BIOSCIENCES | 4 | 3 | -0,71 % | ||
| PYXIS ONCOLOGY | 4 | - | 0,00 % | ||
| BIONTECH | 3 | 13 | +0,71 % | ||
| APOGEE THERAPEUTICS | 3 | - | 0,00 % | ||
| INSMED | 2 | 7 | +1,69 % | ||
| ILLUMINA | 2 | - | +1,23 % | ||
| LIFECORE BIOMEDICAL | 2 | - | +2,29 % | ||
| ARBUTUS BIOPHARMA | 2 | - | -0,05 % | ||
| GOSSAMER BIO | 2 | - | -0,96 % | ||
| GILEAD SCIENCES | 1 | 5 | +1,28 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12:43 | Cabaletta Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 12:42 | Arbutus Biopharma GAAP EPS of -$0.17 misses by $0.13, revenue of $14.08M beats by $13.47M | 1 | Seeking Alpha | ||
| 12:42 | Cabaletta Bio GAAP EPS of -$0.40 beats by $0.06 | 3 | Seeking Alpha | ||
| 12:36 | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update | 83 | GlobeNewswire (Europe) | Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery... ► Artikel lesen | |
| 12:36 | BridgeBio Pharma, Inc.: BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions | 1 | GlobeNewswire (USA) | ||
| 12:36 | Cabaletta Bio, Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
| 12:36 | Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | 86 | GlobeNewswire (Europe) | Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing option No-preconditioning program enrolling in lupus... ► Artikel lesen | |
| 12:32 | Cabaletta Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12:31 | Arbutus Biopharma Corp - 8-K, Current Report | 3 | SEC Filings | ||
| 12:31 | Arbutus Biopharma Corp - 10-K, Annual Report | 6 | SEC Filings | ||
| 12:22 | Viatris: Grünes Licht in Japan für Angststörungs-Medikament Effexor | 5 | Investing.com Deutsch | ||
| 12:22 | Ionis Pharmaceuticals: FDA akzeptiert Zulassungsantrag für Zilganersen mit beschleunigtem Prüfverfahren | 1 | Investing.com Deutsch | ||
| 12:18 | Insmed reports positive Phase 3b trial results for MAC lung disease drug | 4 | Investing.com | ||
| 12:18 | Lifecore Biomedical signs third site transfer deal in five months | 1 | Investing.com | ||
| 12:18 | Royalty Pharma plc: Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence | 32 | GlobeNewswire (Europe) | NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead... ► Artikel lesen | |
| 12:17 | Pyxis Oncology, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 12:12 | Pyxis Oncology GAAP EPS of -$1.28 misses by $0.93, revenue of $13.9M | 1 | Seeking Alpha | ||
| 12:12 | Pyxis Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12:06 | Canaccord reiterates Hold on Illumina stock amid Roche competition | 3 | Investing.com | ||
| 12:06 | Lifecore Biomedical, Inc.: Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company | 37 | GlobeNewswire (Europe) | -- Agreement for the Commercial Manufacture of Established, Approved Aesthetic Product -- -- Third Commercial Site Transfer Agreement Win in Five Months -- -- Program Expected to Generate Commercial... ► Artikel lesen |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.